Corcept’s Lifyorli Combination Shows Early Promise in Platinum-Resistant Ovarian Cancer

Positive Phase 2 data suggest Lifyorli plus chemotherapy and bevacizumab may offer meaningful benefit in hard-to-treat platinum-resistant ovarian cancer.